2026 ESC Guidelines for the Management of Heart Failure — What Has Changed?
The European Society of Cardiology has released the 2026 ESC Guidelines for the Management of Heart Failure, representing a major update to the contemporary approach to prevention, diagnosis, classification and treatment of heart failure.
The new guideline moves beyond simply categorising patients according to left ventricular ejection fraction (LVEF). It introduces a more clinically oriented framework incorporating disease stages, phenotype, comorbidities, congestion, risk and treatment response.
1. A New Approach to Heart Failure Classification
One of the important changes is refinement of the classification of HF according to LVEF.
Rather than viewing HF as a single disease, the guideline emphasises the spectrum of ventricular function and the importance of recognising patients at different stages of disease.
Broadly, clinical phenotypes continue to include:
- HFrEF
- HF with mildly reduced EF
- HFpEF
- HF with improved/recovered EF
The new framework places greater emphasis on early disease recognition and prevention of progression.
This is particularly important because many patients have cardiovascular risk factors or structural heart disease long before overt symptomatic HF develops.
2. Stage-Based Heart Failure Concept
The 2026 guideline introduces a stage-based classification designed to identify HF earlier.
The fundamental concept is:
Risk → Pre-HF → Clinical HF → Advanced HF
This approach recognises that waiting until patients develop overt symptoms and congestion represents a missed opportunity for intervention.
Risk-factor modification, screening, treatment of structural heart disease and early initiation of appropriate therapies therefore become increasingly important.
3. Guideline-Directed Medical Therapy Remains the Foundation
For patients with HFrEF, contemporary treatment continues to centre around the four major pharmacological pillars:
1. ARNI / ACE inhibitor / ARB
Particularly sacubitril/valsartan when appropriate.
2. Evidence-based beta-blocker
Examples include:
- Bisoprolol
- Carvedilol
- Metoprolol succinate
3. Mineralocorticoid receptor antagonist
Examples:
- Spironolactone
- Eplerenone
4. SGLT2 inhibitor
Examples:
- Dapagliflozin
- Empagliflozin
The key practical principle remains:
Do not unnecessarily delay effective therapy while waiting for sequential optimisation.
Modern HF care increasingly focuses on rapid initiation and early optimisation of multiple evidence-based therapies, rather than prolonged sequential titration of one drug at a time.
4. SGLT2 Inhibitors Across the EF Spectrum
SGLT2 inhibitors have become a central component of HF management.
Their role extends beyond classical HFrEF and includes patients across a broad range of LVEF.
The 2026 ESC programme specifically highlights guideline-supported SGLT2 inhibitor use across the ejection-fraction spectrum, reflecting the expanding evidence base.
Their advantages include:
- Reduction in HF hospitalisation
- Cardiovascular benefit
- Renal protection
- Minimal effect on blood pressure compared with many traditional HF drugs
- Benefit irrespective of diabetes status in appropriate HF populations
5. HFpEF: Treat the Patient, Not Just the EF
HFpEF remains a major therapeutic challenge.
The modern approach is increasingly phenotype-driven.
Management includes:
- SGLT2 inhibitors
- Diuretic therapy when congested
- Blood-pressure control
- Management of atrial fibrillation
- Treatment of obesity
- Diabetes management
- Management of chronic kidney disease
- Treatment of coronary artery disease
- Identification of infiltrative or specific cardiomyopathic phenotypes
The goal is not simply to increase EF, but to reduce symptoms, hospitalisation and cardiovascular events while addressing the underlying phenotype.
6. HFmrEF Is No Longer a Therapeutic Grey Zone
Patients with mildly reduced EF represent an important intermediate phenotype.
The expanding evidence base supports active treatment rather than simply observing these patients.
SGLT2 inhibitors have an important role, while other HFrEF-directed therapies may be considered according to the individual clinical phenotype, blood pressure, renal function, potassium and tolerability.
7. Heart Failure With Improved EF
Patients whose LVEF improves substantially after treatment should not automatically have HF therapy withdrawn.
Improvement in EF does not necessarily mean that the underlying disease has disappeared.
Withdrawal of effective therapy can result in deterioration or recurrence.
Therefore, the concept should be:
Improved EF ≠ cured HF
Continued disease-modifying treatment is generally important unless there is a compelling reason to modify therapy.
8. Acute Heart Failure: Start Treatment Early
The contemporary approach to acute HF increasingly emphasises:
Stabilise → Decongest → Identify trigger → Start/optimise disease-modifying therapy → Prevent readmission
Important precipitating factors include:
- Acute coronary syndrome
- Uncontrolled hypertension
- Arrhythmia
- Infection
- Medication non-adherence
- Renal deterioration
- Pulmonary embolism
- Valvular disease
- Excess dietary sodium/fluid
- Inappropriate drug exposure
An important theme emerging around the 2026 guideline is early initiation of appropriate therapy during hospitalisation rather than waiting until outpatient follow-up. ESC Congress 2026 sessions specifically address starting HF treatment early in hospital and translating SGLT2 inhibitor evidence into practice.
9. Diuretics: Essential for Congestion
Loop diuretics remain fundamental for patients with clinical congestion.
The objective is not simply to prescribe a fixed dose but to achieve effective decongestion while monitoring:
- Blood pressure
- Renal function
- Electrolytes
- Urine output
- Weight
- Clinical signs of congestion
Persistent congestion at discharge is associated with poor outcomes.
10. Device Therapy: More Than Just EF
Device therapy continues to be an important component of HF management.
Assessment for:
- ICD
- CRT
- Conduction-system pacing
- Other device-based approaches
should be integrated with:
- LVEF
- QRS duration
- QRS morphology
- NYHA functional status
- Expected survival
- Aetiology
- Arrhythmic risk
- Response to medical therapy
Importantly, the 2026 ESC programme specifically addresses how the new HF guideline changes the relationship between guideline-directed medical therapy and device therapies.
11. Cardiac Resynchronisation Therapy
CRT remains an important treatment for selected patients with HF and electrical dyssynchrony.
Patient selection should consider:
- LVEF
- QRS duration
- LBBB morphology
- Symptoms despite optimal medical therapy
- Rhythm
- Expected pacing requirement
The increasing role of conduction-system pacing also deserves attention in modern device practice.
12. Pulmonary Artery Pressure Monitoring
Remote haemodynamic monitoring is receiving increasing attention.
The 2026 ESC programme includes dedicated discussion of pulmonary artery pressure-guided management of HF, reflecting growing interest in using haemodynamic information to detect deterioration before overt decompensation.
13. Non-Pharmacological Management
Drug therapy is only one component of modern HF management.
The guideline emphasises:
- Exercise and cardiac rehabilitation
- Dietary optimisation
- Appropriate vaccination
- Smoking cessation
- Alcohol moderation
- Weight management
- Patient education
- Self-monitoring
- Multidisciplinary HF care
Cardiac rehabilitation has also received a separate ESC guideline in 2026.
14. Comorbidities Matter
Heart failure frequently coexists with:
- Chronic kidney disease
- Diabetes mellitus
- Obesity
- Anaemia/iron deficiency
- Atrial fibrillation
- Coronary artery disease
- Hypertension
- COPD
- Sleep-disordered breathing
Modern HF treatment therefore requires integrated management rather than isolated treatment of the heart.
15. Iron Deficiency
Iron deficiency is common in HF and can contribute to:
- Fatigue
- Reduced exercise capacity
- Poor quality of life
- Recurrent hospitalisation
Assessment and treatment of iron deficiency should therefore form part of comprehensive HF management when clinically appropriate.
16. Advanced Heart Failure
Patients with progressive symptoms despite optimal treatment should be recognised early for referral to an advanced HF centre.
Warning signs include:
- Recurrent HF admissions
- Persistent NYHA III–IV symptoms
- Hypotension limiting therapy
- Worsening renal function
- Refractory congestion
- Increasing diuretic requirement
- Low-output symptoms
- Intolerance of guideline-directed therapy
- Ventricular arrhythmias
Potential advanced therapies include:
- LVAD
- Heart transplantation
- Advanced device therapy
- Palliative/supportive care when appropriate
17. Prevention Is Now Central to HF Management
One of the most important conceptual changes is the emphasis on preventing HF before clinical disease develops.
Major preventive targets include:
Hypertension + Diabetes + Obesity + CKD + CAD + Lifestyle + Cardiomyopathy
Early identification and aggressive treatment of these conditions may prevent or delay progression to symptomatic HF.
18. The Practical 2026 HF Algorithm
A simplified clinical approach is:
1. Suspect HF
↓
2. Confirm diagnosis
- Symptoms/signs
- ECG
- Natriuretic peptides
- Echocardiography
- Appropriate imaging/laboratory evaluation
↓
3. Define phenotype
- LVEF
- Rhythm
- QRS
- Aetiology
- Congestion
- Comorbidities
↓
4. Identify reversible causes
↓
5. Start evidence-based therapy early
↓
6. Rapidly optimise treatment
↓
7. Reassess
- Symptoms
- BP
- Renal function
- Potassium
- LVEF
- Congestion
↓
8. Evaluate device/advanced HF indications
↓
9. Long-term multidisciplinary follow-up
19. What Is New in the 2026 ESC Guideline?
The major take-home messages are:
π΄ 1. Earlier recognition
HF management begins before overt symptomatic disease.
π΄ 2. Stage-based classification
The guideline puts greater emphasis on progression from risk to established HF.
π΄ 3. Refined EF classification
LVEF remains important, but treatment decisions increasingly consider the entire clinical phenotype.
π΄ 4. SGLT2 inhibitors have a broad role
Their importance extends across the HF spectrum.
π΄ 5. Earlier treatment initiation
Therapy should be started and optimised without unnecessary delays.
π΄ 6. Device therapy is integrated with medical therapy
ICD/CRT decisions should be considered alongside modern GDMT and the patient's overall phenotype.
π΄ 7. Comorbidity management is fundamental
CKD, diabetes, obesity, AF, iron deficiency and other conditions directly influence HF outcomes.
π΄ 8. Prevention has moved to the centre
The goal is increasingly to prevent progression to clinical HF.
Bottom Line
The 2026 ESC Heart Failure Guidelines represent a shift from an EF-centred model toward a stage-based, phenotype-driven and prevention-oriented model of heart failure care.
The practical message for clinicians is simple:
Recognise HF earlier → identify the phenotype → start effective therapy early → optimise rapidly → treat congestion and comorbidities → reassess → consider devices/advanced therapies when indicated.
The ESC describes the 2026 guideline as refining HF classification, introducing stage-based classification, and updating treatment recommendations in light of new evidence.
Official guideline: "2026 ESC Guidelines for the Management of Heart Failure" (https://reference-url-citation.invalid/8)
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you